Form 4: Theravance Biopharma CEO Acquires Shares Under Equity Incentive Plan
SEC Form 4 Filing
Rick E. Winningham, CEO of Theravance Biopharma, acquired 2,178 ordinary shares at $9.35 per share under the company's equity incentive plan.
Summary
- On February 28, 2025, Rick E. Winningham, the CEO of Theravance Biopharma, acquired 2,178 ordinary shares of the company at a price of $9.35 per share.
- The acquisition was made under the Issuer's Amended and Restated 2013 Equity Incentive Plan.
- Following the transaction, Winningham directly owns 1,778,144 ordinary shares.
- He also indirectly owns 3,900 shares as custodian and 92,567 shares by trust.
Sentiment
Score: 7
Explanation: Neutral sentiment as it reflects a routine transaction. The CEO's share acquisition can be seen as a positive signal, but it's not a major event.
Positives
- The CEO's participation in the equity incentive plan demonstrates alignment with shareholder interests.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to the market.
Stakeholder Impact
- The CEO's share acquisition could have a slightly positive impact on shareholder confidence.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: CEO acquired shares under equity incentive plan. |
| 03/04/2025 | Date of filing: Form 4 filing date. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.